NCT05371613Phase 2, phase 3Active not recruiting

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Study sponsor: Denali Therapeutics Inc. · DNLI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants65Actual
Source updated2026-09-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent change from baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A). After: Measure: Ratio to baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 63 participants (planned). After: 65 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview